Brought to you by 
Sun Pharma buys fellow Indian generics competitor Ranbaxy for Rs194bn, plus assumption of debt
10 Sep 2020
Executive Summary
In a move to create India’s largest pharmaceutical company, which would hold a 9.2% share of the generics market there, Sun Pharmaceutical Industries Ltd. acquired fellow Indian generics player and competitor Ranbaxy Laboratories Ltd. (branded generics, OTC products, and active pharmaceutical ingredients (APIs)).
Deal Industry
- Pharmaceuticals
- Services
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
- OTC, Consumer
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sun Pharma buys fellow Indian generics competitor Ranbaxy for Rs194bn, plus assumption of debt
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice